Advanced treatment for basal cell carcinomas

Cold Spring Harbor Perspectives in Medicine

Volumn 4, Issue 7, 2014, Pages

  Atwood, Scott X ^a   Whitson, Ramon J ^a   Oro, Anthony E ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SMOOTHENED PROTEIN; SONIC HEDGEHOG PROTEIN; VISMODEGIB; ANILIDE; ANTINEOPLASTIC AGENT; G PROTEIN COUPLED RECEPTOR; PYRIDINE DERIVATIVE; SMO PROTEIN, HUMAN;

ARTICLE; BASAL CELL CARCINOMA; CANCER RESISTANCE; GENE DUPLICATION; HUMAN; NONHUMAN; POINT MUTATION; PROTEIN PROCESSING; ANTAGONISTS AND INHIBITORS; CARCINOMA, BASAL CELL; DRUG DEVELOPMENT; DRUG RESISTANCE; PHARMACEUTICS; SKIN NEOPLASMS; TREATMENT OUTCOME; TRENDS;

ERINACEIDAE;

ANILIDES; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; DRUG DISCOVERY; DRUG RESISTANCE, NEOPLASM; HEDGEHOG PROTEINS; HUMANS; PYRIDINES; RECEPTORS, G-PROTEIN-COUPLED; SKIN NEOPLASMS; TECHNOLOGY, PHARMACEUTICAL; TREATMENT OUTCOME;

EID: 84923822954     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a013581     Document Type: Article

References (64)

1. Antonarakis ES, Heath EI, Smith DC, Rathkopf D, Blackford AL, Danila DC, King S, Frost A, Ajiboye AS, Zhao M, et al. 2013. Repurposing Itraconazole as a treatment for advanced prostate cancer: A noncomparative randomized Phase II trial in men with metastatic castration-resistant prostate cancer. Oncologist 18: 163-173.
2. Atwood SX, Chang ALS, Oro AE. 2012. Hedgehog pathway inhibition and the race against tumor evolution. J Cell Biol 199: 193-197.
3. Atwood SX, Li M, Lee A, Tang JY, Oro AE. 2013. GLI activation by atypical protein kinase C i/X regulates the growth of basal cell carcinomas. Nature 494: 484-488.
4. Bristol-Myers Squibb. 2013. Phase 1 multiple ascending dose study of BMS-833923 (XL139) in subjects with solid tumors. U.S. National Institutes ofHealth, Bethesda, MD (updated May 31, 2013).
5. Buonamici S, Williams J, Morrissey M, Wang A, Guo R, Vattay A, Hsiao K, Yuan J, Green J, Ospina B, et al. 2010. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblas-toma. Sci Transl Med 2: 51ra70.
6. Callahan CA, Ofstad T, Horng L, Wang JK, Zhen HH, Coulombe PA, Oro AE. 2004. MIM/BEG4, a Sonic hedgehog-responsive gene that potentiates Gli-dependent transcription. Genes Dev 18: 2724-2729.
7. Campbell SB, Walker R, Tai SS, Jiang Q, Russ GR. 2012. Randomized controlled trial ofsirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer. Am J Transplant 12: 1146-1156.
8. Chang ALS, Oro AE. 2012. Initial assessment of tumor re-growth after vismodegib in advanced Basal cell carcinoma. Arch Dermatol 148: 1324-1325.
9. Chen JK, Taipale J, Cooper MK, Beachy PA. 2002. Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. Genes Dev 16: 2743-2748.
10. Chenna V, Hu C, Pramanik D, Aftab BT, Karikari C, Campbell NR, Hong S-M, Zhao M, Rudek MA, Khan SR, et al. 2012. A polymeric nanoparticle encapsulated small-molecule inhibitor of Hedgehog signaling (NanoHHI) bypasses secondary mutational resistance to Smoothened antagonists. Mol Cancer Therapeut 11: 165-173.
11. Chiang C, Litingtung Y, Lee E, Young KE, Corden JL, West-phal H, Beachy PA. 1996. Cyclopia and defective axial patterning in mice lacking Sonic hedgehog gene function. Nature 383: 407-413.
12. Desch P, Asslaber D, Kern D, Schnidar H, Mangelberger D, Alinger B, Stoecher M, Hofbauer SW, Neureiter D, Tinhofer I, et al. 2010. Inhibition of GLI, but not Smoothened, induces apoptosis in chronic lymphocytic leukemia cells. Oncogene 29: 4885-4895.
13. Diaz LA, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA, et al. 2012. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486: 537-540.
14. Dijkgraaf GJP, Alicke B, Weinmann L, Januario T, West K, Modrusan Z, Burdick D, Goldsmith R, Robarge K, Su-therlin D, et al. 2011. Small molecule inhibition ofGDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance. Cancer Res 71: 435-444.
15. Epstein EH. 2008. Basal cell carcinomas: Attack of the hedgehog. Nat Rev Cancer 8: 743-754.
16. Epstein EH. 2011. Mommy—Where do tumors come from? JClinInvest 121: 1681-1683.
17. Fu J, Rodova M, Roy SK, Sharma J, Singh KP, Srivastava RK, Shankar S. 2012. GANT-61 inhibits pancreatic cancer stem cell growth in vitro and in NOD/SCID/IL2R g null mice xenograft. Cancer Lett 330: 22-32.
18. Gomez-Ospina N, Chang ALS, Qu K, Oro AE. 2012. Translocation affecting sonic hedgehog genes in basal-cell carcinoma. N Engl J Med 366: 2233-2234.
19. Grachtchouk M, Pero J, Yang SH, Ermilov AN, Michael LE, Wang A, Wilbert D, Patel RM, Ferris J, Diener J, et al. 2011. Basal cell carcinomas in mice arise from hair follicle stem cells and multiple epithelial progenitor populations. JClinInvest 121: 1768-1781.
20. Hassounah NB, Bunch TA, McDermott KM. 2012. Molecular pathways: The role of primary cilia in cancer progression and therapeutics with a focus on Hedgehog signaling. Clin Cancer Res 18: 2429-2435.
21. Hildebrandt F, Benzing T, Katsanis N. 2011. Ciliopathies. N Engl J Med 364: 1533-1543.
22. Huangfu D, Liu A, Rakeman AS, Murcia NS, Niswander L, Anderson KV. 2003. Hedgehog signalling in the mouse requires intraflagellar transport proteins. Nature 426:83-87.
23. Hui C-C, Angers S. 2011. Gli proteins in development and disease. Annu Rev Cell Dev Biol 27: 513-537.
24. Humke EW, Dorn KV, Milenkovic L, Scott MP, Rohatgi R. 2010. The output ofHedgehog signaling is controlled by the dynamic association between Suppressor of Fused and the Gli proteins. Genes Dev 24: 670-682.
25. Hyman JM, Firestone AJ, Heine VM, Zhao Y, Ocasio CA, Han K, Sun M, Rack PG, Sinha S, Wu JJ, et al. 2009.Small-molecule inhibitors reveal multiple strategies for Hedgehog pathway blockade. Proc Natl Acad Sci 106:14132-14137.
26. Kasper M, Jaks V, Are A, Bergstrom A, Schwàger A, Barker N, Toftgard R. 2011. Wounding enhances epidermal tumor-igenesis by recruiting hair follicle keratinocytes. Proc Natl Acad Sci 108: 4099-4104.
27. Keady BT, Samtani R, Tobita K, Tsuchya M, San Agustin JT, Follit JA, Jonassen JA, Subramanian R, Lo CW, Pazour GJ. 2012. IFT25 links the signal-dependent movement of Hedgehog components to intraflagellar transport. Dev Cell 22: 940-951.
28. Keeler RF, Binns W. 1966. Teratogenic compounds of Vera-trum californicum (Durand). I. Preparation and characterization of fractions and alkaloids for biologic testing. Can JBiochem 44: 819-828.
29. Kim J, Lee JJ, Kim J, Gardner D, Beachy PA. 2010a. Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stabilityofthe Gli2 transcrip-tional effector. Proc Natl Acad Sci 107: 13432-13437.
30. Kim J, Tang JY, Gong R, Kim J, Lee JJ, Clemons KV, Chong CR, Chang KS, Fereshteh M, Gardner D, et al. 2010b. Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell 17: 388-399.
31. Kim J, Aftab BT, Tang JY, Kim D, Lee AH, Rezaee M, Kim J, Chen B, King EM, Borodovsky A, et al. 2013. Itraconazole and arsenic trioxide inhibit Hedgehog pathwayactivation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell 23: 23-34.
32. Lappano R, Maggiolini M. 2011. G protein-coupled receptors: Novel targets for drug discovery in cancer. Nat Rev DrugDiscov 10: 47-60.
33. Lauth M, Bergstrom A, Shimokawa T, Toftgard R. 2007. Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc Natl Acad Sci 104: 8455-8460.
34. Lee MJ, Hatton BA, Villavicencio EH, Khanna PC, Friedman SD, Ditzler S, Pullar B, Robison K, White KF, Tunkey C, et al. 2012. Hedgehog pathway inhibitor saridegib (IPI-926) increases lifespan in a mouse medulloblastoma model. Proc Natl Acad Sci 109: 7859-7864.
35. LoRusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Chang I, Darbonne WC, et al. 2011. Phase I trial ofhedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res 17: 2502-2511.
36. Maun HR, Wen X, Lingel A, de Sauvage FJ, Lazarus RA, Scales SJ, Hymowitz SG. 2010. Hedgehog pathwayantag-onist 5E1 binds hedgehog at the pseudo-active site. JBiol Chem 285: 26570-26580.
37. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, et al. 2012. Emergence ofKRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486: 532-536.
38. Munchhof MJ, Li Q, Shavnya A, Borzillo GV, Boyden TL, Jones CS, LaGreca SD, Martinez-Alsina L, Patel N, Pelletier K, et al. 2012. Discovery of PF-04449913, a potent and orally bioavailable inhibitor of Smoothened. ACS Med Chem Lett 3: 106-111.
39. Nilsson M, Unden AB, Krause D, Malmqwist U, Raza K, Zaphiropoulos PG, Toftgard R. 2000. Induction of basal cell carcinomas and trichoepitheliomas in mice overex-pressing GLI-1. Proc Natl Acad Sci 97: 3438-3443.
40. Oro AE, Higgins K. 2003. Hair cycle regulation of Hedgehog signal reception. Dev Biol 255: 238-248.
41. Oro AE, Higgins KM, Hu Z, Bonifas JM, Epstein EH, Scott MP. 1997. Basal cell carcinomas in mice overexpressing sonic hedgehog. Science 276: 817-821.
42. Pan D, Li Y, Li Z, Wang Y, Wang P, Liang Y. 2012. Gli inhibitor GANT61 causes apoptosis in myeloid leukemia cells and acts in synergy with rapamycin. Leuk Res 36: 742-748.
43. Pearce LR, Alton GR, Richter DT, Kath JC, Lingardo L, Chapman J, Hwang C, Alessi DR. 2010. Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1). Biochem J 431: 245-255.
44. Peifer C, Alessi DR. 2008. Small-molecule inhibitors of PDK1. ChemMedChem 3: 1810-1838.
45. Riobo NA, Lu K, Ai X, Haines GM, Emerson CP. 2006. Phosphoinositide 3-kinase and Akt are essential for Sonic Hedgehog signaling. Proc Natl Acad Sci 103:4505-4510.
46. Robarge KD, Brunton SA, Castanedo GM, Cui Y, Dina MS, Goldsmith R, Gould SE, Guichert O, Gunzner JL, Halladay J, et al. 2009. GDC-0449-a potent inhibitor of the hedgehog pathway. Bioorg Med Chem Lett 19: 5576-5581.
47. Rubin AI, Chen EH, Ratner D. 2005. Basal-cell carcinoma. N Engl J Med 353: 2262-2269.
48. Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hains-worth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, et al. 2012. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 366: 2171-2179.
49. Skvara H, Kalthoff F, Meingassner JG, Wolff-Winiski B, Aschauer H, Kelleher JF, Wu X, Pan S, Mickel L, Schuster C, et al. 2011. Topical treatment of Basal cell carcinomas in nevoid Basal cell carcinoma syndrome with a smooth-ened inhibitor. J Invest Dermatol 131: 1735-1744.
50. Tang JY, Marghoob AA. 2011. Emerging treatments and signaling pathway inhibitors. Semin Cutan Med Surg 30: S14-S18.
51. Tang T, Tang JY, Li D, Reich M, Callahan CA, Fu L, Yauch RL, Wang F, Kotkow K, Chang KS, et al. 2011. Targeting superficial or nodular Basal cell carcinoma with topically formulated small molecule inhibitor of smoothened. Clin Cancer Res 17: 3378-3387.
52. Tang JY, Mackay-Wiggan JM, Aszterbaum M, Yauch RL, Lindgren J, Chang K, Coppola C, Chanana AM, Marji J, Bickers DR, et al. 2012. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med 366: 2180-2188.
53. Tao H, Jin Q, Koo D-I, Liao X, Englund NP, Wang Y, Ram-amurthy A, Schultz PG, Dorsch M, Kelleher J, et al. 2011. Small molecule antagonists in distinct binding modes inhibit drug-resistant mutant ofsmoothened. Chem Biol 18: 432-437.
54. Tremblay MR, Lescarbeau A, Grogan MJ, Tan E, Lin G, Austad BC, Yu L-C, Behnke ML, Nair SJ, Hagel M, etal. 2009. Discoveryofa potent and orallyactive hedgehog pathway antagonist (IPI-926). J Med Chem 52: 4400-4418.
55. Tukachinsky H, Lopez LV, Salic A. 2010. A mechanism for vertebrate Hedgehog signaling: Recruitment to cilia and dissociation of SuFu-Gli protein complexes. J Cell Biol 191: 415-428.
56. Varjosalo M, Taipale J. 2008. Hedgehog: Functions and mechanisms. Genes Dev 22: 2454-2472.
57. Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, et al. 2009. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 361: 1164-1172.
58. Wang GY, Wang J, Mancianti M-L, Epstein EH. 2011. Basal cell carcinomas arise from hair follicle stem cells in Ptch1+/- mice. Cancer Cell 19: 114-124.
59. Wang Y, Ding Q, Yen C-J, Xia W, Izzo JG, Lang J-Y, Li C-W, Hsu JL, Miller SA, Wang X, et al. 2012. The crosstalk of mTOR/S6K1 and Hedgehog pathways. Cancer Cell 21:374-387.
60. Wong SY, Reiter JF. 2011. From the cover: Wounding mobilizes hair follicle stem cells to form tumors. Proc Natl Acad Sci 108: 4093-4098.
61. Wong SY, Seol AD, So P-L, Ermilov AN, Bichakjian CK, Epstein EH, Dlugosz AA, Reiter JF. 2009. Primary cilia can both mediate and suppress Hedgehog pathway-dependent tumorigenesis. Nat Med 15: 1055-1061.
62. Xu Y, Chenna V, Hu C, Sun H-X, Khan M, Bai H, Yang X-R, Zhu Q-F, Sun Y-F, Maitra A, et al. 2012. Polymeric nano-particle-encapsulated hedgehog pathway inhibitor HPI-1 (NanoHHI) inhibits systemic metastases in an orthotopic model of human hepatocellular carcinoma. Clin Cancer Res 18: 1291-1302.
63. Yauch RL, Dijkgraaf GJP, Alicke B, Januario T, Ahn CP, Holcomb T, Pujara K, Stinson J, Callahan CA, Tang T, et al. 2009. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science 326: 572-574.
64. Youssef KK, Van Keymeulen A, Lapouge G, Beck B, Michaux C, Achouri Y, Sotiropoulou PA, Blanpain C. 2010. Identification of the cell lineage at the origin of basal cell carcinoma. Nat Cell Biol 12: 299-305.